149 related articles for article (PubMed ID: 21859930)
1. Mimics of the dimerization domain of hepatocyte growth factor exhibit anti-Met and anticancer activity.
Kawas LH; Yamamoto BJ; Wright JW; Harding JW
J Pharmacol Exp Ther; 2011 Nov; 339(2):509-18. PubMed ID: 21859930
[TBL] [Abstract][Full Text] [Related]
2. The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.
Yamamoto BJ; Elias PD; Masino JA; Hudson BD; McCoy AT; Anderson ZJ; Varnum MD; Sardinia MF; Wright JW; Harding JW
J Pharmacol Exp Ther; 2010 Apr; 333(1):161-73. PubMed ID: 20086056
[TBL] [Abstract][Full Text] [Related]
3. Development of angiotensin IV analogs as hepatocyte growth factor/Met modifiers.
Kawas LH; McCoy AT; Yamamoto BJ; Wright JW; Harding JW
J Pharmacol Exp Ther; 2012 Mar; 340(3):539-48. PubMed ID: 22129598
[TBL] [Abstract][Full Text] [Related]
4. Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.
Church KJ; Vanderwerff BR; Riggers RR; McMicheal MD; Mateo-Victoriano B; Sukumar SR; Harding JW
Anticancer Drugs; 2016 Sep; 27(8):766-79. PubMed ID: 27314431
[TBL] [Abstract][Full Text] [Related]
5. Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.
Church KJ; Vanderwerff BR; Riggers RR; Mateo-Victoriano B; Fagnan M; Harris PH; LeValley JC; Harding JW
Anticancer Drugs; 2018 Apr; 29(4):295-306. PubMed ID: 29389804
[TBL] [Abstract][Full Text] [Related]
6. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent.
Merchant M; Ma X; Maun HR; Zheng Z; Peng J; Romero M; Huang A; Yang NY; Nishimura M; Greve J; Santell L; Zhang YW; Su Y; Kaufman DW; Billeci KL; Mai E; Moffat B; Lim A; Duenas ET; Phillips HS; Xiang H; Young JC; Vande Woude GF; Dennis MS; Reilly DE; Schwall RH; Starovasnik MA; Lazarus RA; Yansura DG
Proc Natl Acad Sci U S A; 2013 Aug; 110(32):E2987-96. PubMed ID: 23882082
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte Growth Factor and Macrophage-stimulating Protein "Hinge" Analogs to Treat Pancreatic Cancer.
Wright JW; Church KJ; Harding JW
Curr Cancer Drug Targets; 2019; 19(10):782-795. PubMed ID: 30914029
[TBL] [Abstract][Full Text] [Related]
8. Structural and functional basis of the serine protease-like hepatocyte growth factor beta-chain in Met binding and signaling.
Kirchhofer D; Yao X; Peek M; Eigenbrot C; Lipari MT; Billeci KL; Maun HR; Moran P; Santell L; Wiesmann C; Lazarus RA
J Biol Chem; 2004 Sep; 279(38):39915-24. PubMed ID: 15218027
[TBL] [Abstract][Full Text] [Related]
9. The Sema domain of Met is necessary for receptor dimerization and activation.
Kong-Beltran M; Stamos J; Wickramasinghe D
Cancer Cell; 2004 Jul; 6(1):75-84. PubMed ID: 15261143
[TBL] [Abstract][Full Text] [Related]
10. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met.
Basilico C; Arnesano A; Galluzzo M; Comoglio PM; Michieli P
J Biol Chem; 2008 Jul; 283(30):21267-77. PubMed ID: 18495663
[TBL] [Abstract][Full Text] [Related]
11. PTEN reconstitution alters glioma responses to c-Met pathway inhibition.
Goodwin CR; Lal B; Ho S; Woodard CL; Zhou X; Taeger A; Xia S; Laterra J
Anticancer Drugs; 2011 Oct; 22(9):905-12. PubMed ID: 21654317
[TBL] [Abstract][Full Text] [Related]
12. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
13. Targeting the hepatocyte growth factor/Met pathway in cancer.
De Silva DM; Roy A; Kato T; Cecchi F; Lee YH; Matsumoto K; Bottaro DP
Biochem Soc Trans; 2017 Aug; 45(4):855-870. PubMed ID: 28673936
[TBL] [Abstract][Full Text] [Related]
14. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
[TBL] [Abstract][Full Text] [Related]
15. Structural basis of MET receptor dimerization by the bacterial invasion protein InlB and the HGF/SF splice variant NK1.
Niemann HH
Biochim Biophys Acta; 2013 Oct; 1834(10):2195-204. PubMed ID: 23123275
[TBL] [Abstract][Full Text] [Related]
16. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K
Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590
[TBL] [Abstract][Full Text] [Related]
17. Engineering hepatocyte growth factor fragments with high stability and activity as Met receptor agonists and antagonists.
Jones DS; Tsai PC; Cochran JR
Proc Natl Acad Sci U S A; 2011 Aug; 108(32):13035-40. PubMed ID: 21788476
[TBL] [Abstract][Full Text] [Related]
18. Soluble c-Met receptors inhibit phosphorylation of c-Met and growth of hepatocyte growth factor: c-Met-dependent tumors in animal models.
Coxon A; Rex K; Meyer S; Sun J; Sun J; Chen Q; Radinsky R; Kendall R; Burgess TL
Mol Cancer Ther; 2009 May; 8(5):1119-25. PubMed ID: 19435874
[TBL] [Abstract][Full Text] [Related]
19. Effective inhibition of c-MET-mediated signaling, growth and migration of ovarian cancer cells is influenced by the ovarian tissue microenvironment.
Kwon Y; Smith BD; Zhou Y; Kaufman MD; Godwin AK
Oncogene; 2015 Jan; 34(2):144-53. PubMed ID: 24362531
[TBL] [Abstract][Full Text] [Related]
20. The HGF inhibitory peptide HGP-1 displays promising in vitro and in vivo efficacy for targeted cancer therapy.
Chen L; Li C; Zhu Y
Oncotarget; 2015 Oct; 6(30):30088-101. PubMed ID: 26254225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
